Last €7.12 EUR
Change Today -0.03 / -0.42%
Volume 35.5K
TNG On Other Exchanges
EN Paris
As of 11:35 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

transgene sa (TNG) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - €13.71
52 Week Low
10/16/14 - €6.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TRANSGENE SA (TNG)

Related News

No related news articles were found.

transgene sa (TNG) Related Businessweek News

No Related Businessweek News Found

transgene sa (TNG) Details

Transgene S.A., a biopharmaceutical company, engages in the research, design, development, and manufacture of therapeutic vaccines and immunotherapeutic products to treat cancers and chronic infectious diseases. Its principal products under Phase II clinical trials include TG4010 for the treatment of metastatic non-small cell lung cancer in combination with chemotherapy; Pexa-Vec primarily for the treatment for liver cancer; TG4001, a therapeutic vaccine for oropharyngeal cancer caused by an infection by the human papilloma virus (HPV); and TG4040 for the treatment of chronic hepatitis C. The company has agreements with Novartis for the development of TG4010 to treat various cancers; Jennerex Biotherapeutics, Inc. for the development and marketing of Pexa-Vec, an oncolytic product; and European Organization for Research and Treatment of Cancer for the development of TG4001 to treat HPV induced head and neck cancers. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene S.A. is a subsidiary of TSGH SAS.

262 Employees
Last Reported Date: 04/17/14
Founded in 1979

transgene sa (TNG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €72.2K
Compensation as of Fiscal Year 2013.

transgene sa (TNG) Key Developments

Transgene SA Reports Unaudited Revenue Results for the Third Quarter and Nine Months Ended September 30, 2014

Transgene SA reported unaudited revenue results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating revenue of EUR 2.9 million against EUR 4.8 million a year ago. For the nine months, the company reported operating revenue of EUR 9.2 million against EUR 11.5 million a year ago.

Transgene SA Announces Management Changes

Transgene SA announced the further strengthening of its management team following the recent arrival of Eric Quémeneur as Executive Vice President, Vice President Research & Development. The management committee of Transgene, chaired by Philippe Archinard, Chairman and Chief Executive Officer, is now composed of: Eric Quémeneur; Dr. Nathalie Adda, Vice President, Chief Medical Officer; Christophe Ancel, Vice President Quality and Qualified Person; Jean-Philippe Del, Vice President Finance; Thibaut du Fayet, Vice President Alliance Management, Project Management and Marketing; Colin Freund, Vice President Business Development; Patrick Mahieux, Vice President Industrial and Pharmaceutical Operations; and Hemanshu Shah, Vice President Medical Affairs. Stéphane Boissel, Executive Vice President and Chief Financial Officer, announced that he is leaving the Company to pursue other opportunities.

Transgene Presents Additional Positive Clinical Data from Phase 2B Part of Time Trial with TG4010 at ESMO

Transgene SA announced the presentation of more mature data from the phase 2b part of the TIME trial with TG4010 MUC1 targeted immunotherapy at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain. The data presented show promising and consistent results in progression-free survival (PFS) and overall survival (OS), particularly in the large subgroup of patients with non-squamous disease. The TIME trial is a randomized, double-blind, placebo-controlled study evaluating TG4010 in combination with chemotherapy in the first-line treatment of MUC1 positive advanced (Stage IV) NSCLC patients. A total of 222 patients were enrolled in the phase 2b portion of the trial, and enrollment is now completed. The primary endpoint of the phase 2b part of the study is to prospectively validate the TrPAL predictive biomarker; the safety and efficacy of TG4010 in combination with chemotherapy in this patient population were also assessed, including in pre-specified subgroups. Consistent with previous communications, these improvements were even more notable in the so-called 'low' TrPAL groups of patients. G4010 was well tolerated, and the nature and incidence of adverse events in the TG4010 arm were consistent with previous phase 2 clinical trials. The most frequent TG4010-related adverse events were mild to moderate injection site reactions. To date, over 350 patients have been treated with TG4010 and the product has been consistently well tolerated across trials. Recent interactions with regulatory authorities have encouraged Transgene to move forward with the preparations for the Phase 3 part of the TIME trial. This trial is planned to enroll only patients with non-squamous disease. Transgene is seeking a global development and commercialization partner for TG4010 and talks are ongoing with potential partners.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNG:FP €7.12 EUR -0.03

TNG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNG.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNG Industry Range
No financial data is available for TNG.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at